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ABSTRACT Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective 
response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This 
study aimed to investigate the efficacy and safety of the oral vinorelbine-apatinib combination in patients with pretreated mBC. In 
addition, we detected gene variants in ctDNA to explore the therapeutic implications.
Methods: This study enrolled patients with HER2-negative mBC who were pretreated with anthracycline/taxanes. Patients were 
treated with apatinib at 500 mg/425 mg daily plus oral vinorelbine 60 mg/m2 on days 1, 8, and 15 of every cycle (3 weeks). The 
primary endpoint was PFS. The secondary endpoints were ORR, CBR, OS, and safety. Patients eligible for ctDNA detection were 
evaluated before and during treatment.
Results: Forty patients were enrolled. The median PFS was 5.2 months (95% CI, 3.4–7.0 months), and the median OS was 17.4 
months (95% CI, 8.0–27.0 months). The ORR was 17.1% (6/35), and the CBR was 45.7% (16/35). The most common AEs included 
gastrointestinal reaction, myelosuppression, and hypertension. In 20 patients, ctDNA was detected at baseline and during treatment. 
A significant difference was found in PFS for undetected vs. detected baseline ctDNA (13.9 months vs. 3.6 months, P = 0.018).
Conclusions: All-oral therapy with apatinib plus vinorelbine displayed objective efficacy in patients with heavily pretreated HER2-
negative mBC, with acceptable and manageable toxicity profiles. Patients with no gene variant detected and lower variant allele 
frequencies in ctDNA at baseline showed longer PFS.
KEYWORDS  Metastatic breast cancer; apatinib; oral vinorelbine; ctDNA
Introduction
Despite a recent decline in breast cancer (BC) mortality, meta-
static BC (mBC) remains an incurable disease1. Angiogenesis is 
an important factor in tumor growth, invasion, and metastasis2. 
Vascular endothelial growth factor (VEGF) and its receptor, 
Correspondence to: Peng Yuan
E-mail: yuanpengyp01@163.com
ORCID ID: https://orcid.org/0000-0003-3019-0688
Received July 21, 2020; accepted November 11, 2020.
Available at www.cancerbiomed.org
©2021 Cancer Biology & Medicine. Creative Commons  
Attribution-NonCommercial 4.0 International License
876 Zhu et al. Apatinib plus oral vinorelbine in metastatic breast cancer
vascular endothelial growth factor receptor (VEGFR), are key 
factors regulating neovascularization3. Studies on antiangi-
ogenic agents have continued to develop applications in the 
treatment of mBC. Although prolonged progression-free sur-
vival (PFS) has been observed with chemotherapy, the lack of 
improvement in overall survival (OS) along with the presence 
of severe adverse events (AEs) has limited the application of 
antiangiogenic agents4-11.
Apatinib is a novel small-molecule oral tyrosine kinase 
inhibitor that selectively binds VEGFR-2, thus decreasing 
VEGF-mediated endothelial cell migration, proliferation, 
and tumor microvessel density12. Apatinib, an inhibitor of 
VEGFR-2 through selective competition for ATP binding sites, 
is more specific to VEGFR-213. Preclinical studies suggest that 
apatinib can reverse P-glycoprotein (P-gp/ABCB1)- and BC 
resistance protein (BCRP/ABCG2)-mediated multidrug resist-
ance, thus amplifying the cytotoxicity of chemotherapeutic 
drugs such as anthracyclines, taxanes, and vinca alkaloids14,15. 
Two multicenter phase II studies have reported an objective 
response rate (ORR) of apatinib in mBC treatment of 0.7%–
16.7%, a median PFS of 3.3–4.0 months, and a median OS of 
10.3–10.6 months16,17. On the basis of preclinical and clinical 
data, researchers have become increasingly interested in evalu-
ating the efficacy of apatinib combined with chemotherapy in 
patients with mBC18-20.
Vinorelbine is a semisynthetic vinca alkaloid antitumor 
agent. Single-agent or combination chemotherapy with 
vinorelbine has shown efficacy in patients with mBC. The 
ORR of oral single-agent regimens in the first-line treatment 
of metastatic HER2-negative BC has been reported to be 
11%–31%21-24 and to reach 50%–60% when these regimens 
are combined with agents such as capecitabine25-29. In addi-
tion, vinorelbine exhibits anti-angiogenic properties30. For 
low-dose chemotherapy combined with anti- angiogenesis, 
Klement et al.31 have validated the rationale in which any 
anti-vascular effects of the low-dose chemotherapy would be 
selectively enhanced when survival signals mediated by VEGF 
were inhibited. Preclinical and clinical studies have revealed 
that anti-angiogenetic agents and vinorelbine have synergistic 
anti-tumor functions in NSCLC and BC32-35. On the basis of 
this evidence, and given the relatively benign AE profile and 
convenience of administration, we selected oral vinorelbine as 
a combination agent to be used with the antiangiogenic tyro-
sine kinase inhibitor (TKI) apatinib.
Analysis of circulating tumor DNA (ctDNA) is a widespread 
method of liquid biopsy, which enables disease diagnosis36,37, 
prognostication38,39, detection of recurrence40,41, monitoring 
of tumor burden, and identification of therapeutic responses42 
and resistance43,44 in patients with BC.
This phase II study aimed to prospectively explore the effi-
cacy and safety of apatinib combined with oral vinorelbine in 
patients with metastatic HER2-negative BC. This study fur-
ther detected somatic mutations in plasma ctDNA at baseline 
and during treatment in patients treated with apatinib plus 
oral vinorelbine, to explore the potential association between 




The present study was approved by the National Cancer 
Center/National Clinical Research Center for Cancer/Cancer 
Hospital, Chinese Academy of Medical Sciences and Peking 
Union Medical College (Approval No. CH-BC-046) and 
registered at clinicaltrials.gov (No. NCT02768415). Written 
informed consent to participate in the study was obtained from 
all patients or their legal guardians. The study was performed 
in accordance with the relevant guidelines and regulations.
Included patients
The study population included patients with HER2-negative 
mBC for whom previous treatment failed. The specific 
inclusion criteria and exclusion criteria are described in 
Supplementary material 1.
Therapeutic protocol
The initial oral dose of apatinib was 500 mg/day with 21 days/
cycle. Investigators could adjust the initial dose down to 425 
mg/day according to age, ECOG score, and body surface area. 
If patients had grade 3/4 hematologic AEs, hypertension, pro-
teinuria, hand-foot skin reaction, mucositis, or grade 3/4 non-
hematologic AEs requiring intervention, delayed administra-
tion and dose adjustment were considered: if the initial dose 
was 500 mg/day, then it was reduced to 425 mg/day for the first 
dose and 250 mg/day for the second dose; if the initial dose was 
425 mg/day, it was reduced to 250 mg/day. Apatinib was taken 
continuously until disease progression, intolerance of AEs after 
dose modification, withdrawal of informed consent, or admin-
istration delays of > 14 days due to toxicity.
Oral vinorelbine 60 mg/m2 (body surface area) was admin-
istered on days 1, 8, and 15 of the 21-day cycle. If patients had 
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grade 3/4 hematologic AEs or grade 3/4 nonhematologic AEs 
that required intervention, delayed administration and dose 
adjustment were considered. Vinorelbine was taken continu-
ously until disease progression, intolerance to AEs after dose 
adjustment, withdrawal of informed consent, or administra-
tion delays of > 21 days due to toxicity.
Study design
This was a single-arm, open-label phase II study. The primary 
endpoint was PFS. The secondary endpoints were ORR, clin-
ical benefit rate (CBR), OS, and safety. PFS was defined as the 
time from registration to the date of disease progression or 
death from any cause. OS was defined as the time from reg-
istration to the date of death from any cause or the last fol-
low-up visit. Efficacy was evaluated every 2 cycles until disease 
progression, intolerable AEs, withdrawal of informed consent, 
or delayed dosing beyond the prescribed period. Delayed 
administration was defined as failure to take the drug on time 
for ≥ 3 days during treatment.
According to the response evaluation criteria in solid tumors 
(RECIST) 1.1, efficacy was categorized as complete response 
(CR), partial response (PR), stable disease (SD), or progressive 
disease (PD). ORR was defined as the proportion of eligible 
patients who achieved confirmed CR or PR. CBR was defined 
as the proportion of patients who achieved CR, PR, or SD for 
at least 24 weeks.
AEs were assessed and graded in accordance with the com-
mon terminology criteria for adverse events (CTCAE) 4.0.
ctDNA detection
Patients who consented to at least one blood draw were eligible 
for further ctDNA analysis and constituted the study popula-
tion. Library preparation, NGS sequencing, and bioinformat-
ics analysis were performed as described in Supplementary 
material 2.
Statistical analysis
Previously reported data have indicated that the median 
PFS with oral vinorelbine combination with capecitabine as 
a second-line treatment for metastatic HER2-negative BC is 
3.8 months45. The study was designed to be two-sided, with 
an α-error of 5% and a power of 80%. We expected that the 
median PFS for patients receiving apatinib combined with 
oral vinorelbine would be 6 months. Assuming a 15% dropout 
rate and 6-month follow-up period, the final accrual number 
was 40.
Data were summarized as frequency and percentage for 
qualitative variables, and as medians and ranges for quan-
titative variables. The PFS and OS were calculated from the 
date of registration to the first documented date of disease 
progression and date of death, respectively, with the Kaplan-
Meier method. Associated 95% CIs were calculated with the 
Brookmeyer-Crowley method. The log-rank test was used for 
comparison of PFS and OS between groups. The multiple Cox 
model was used to evaluate significant differences in PFS and 
OS between groups. Statistical analyses were conducted with 
SPSS 21.0 statistical software (SPSS, Chicago, IL, USA).
Results
Patient information
The baseline patient characteristics are shown in Table 1. 
Forty patients with HER2-negative mBC were enrolled at 
our institution between May 2016 and January 2018 (median 
age, 55 years; range 30–70 years). Twenty-one patients 
(52.5%) received apatinib combined with oral vinorelbine 
as a second-line treatment, and 19 patients (47.5%) received 
it as a third-line treatment or beyond. All 40 patients were 
included in the survival and safety analyses. Five patients 
were discharged before the first efficacy evaluation. A total 
of 35 patients were included in the efficacy evaluation anal-
ysis. At the time of the final follow-up (November 30, 2019), 
33 (82.5%) patients had disease progression, and 28 (70.0%) 
patients had died. Twenty-seven (67.5%) patients had delayed 
administration of apatinib or oral vinorelbine during treat-
ment. Twenty-one (52.5%) patients experienced apatinib or 
oral vinorelbine dose modification.
Safety
No treatment-related deaths occurred, but 28 patients died 
because of disease progression.
The initial dose of apatinib was 500 mg/day for the first 
17 patients. During the first cycle of treatment, 6 patients 
(35.3%) developed grade 3 hypertension with poor control 
from the combined antihypertensive therapy, 1 patient (5.9%) 
had grade 3 proteinuria, 1 patient (5.9%) developed a grade 
3 hand-foot skin reaction, and 1 patient (5.9%) was hospital-
ized for grade 3 symptomatic thrombocytopenia. Because of 
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Table 1 Patient characteristics at baseline
Characteristics   n (%)
Age (years)
 < 55   20 (50.0)
 ≥ 55   20 (50.0)
ECOG performance status
 0   27 (67.5)
 1   13 (32.5)
Hormone receptor
 Negative   20 (50.0)
 Positive   20 (50.0)
Histopathologic grade
 I–II   18 (45.0)
 III   16 (40.0)
 Unknown   6 (15.0)
Tumor size (cm)
 ≤ 2.0   13 (32.5)
 > 2.0   21 (52.5)
 Unknown   6 (15.0)
Axillary lymph node metastasis 
 Positive   29 (72.5)
 Negative   7 (17.5)
 Unknown   4 (10.0)
TNM stage at diagnosis
 I–II   15 (37.5)
 III   18 (45.0)
 Unknown   7 (17.5)
Local recurrence
 Regional lymph node  20 (50.0)
 Chest wall   17 (42.5)
Distant metastasis
 Distant lymph node   20 (50.0)
 Bone   19 (47.5)
 Lung   13 (32.5)
 Liver   10 (25.0)
 Pleura   4 (10.0)
 Skin   3 (7.5)
Characteristics   n (%)
 Brain   2 (5.0)
 Metastasis ≥ 3 sites   21 (52.5)
Starting dose of apatinib
 425 mg   23 (57.5)
 500 mg   17 (42.5)
Lines of apatinib plus vinorelbine treatment
 < 3 line   21 (52.5)
 ≥ 3 line   19 (47.5)
Table 1 Continued
tolerance concerns, all patients enrolled after the 17th patient 
were given a lower initial dose of 425 mg/day. Among patients 
who underwent dose modification with apatinib (n = 8), 5 
had a final dose of 425 mg/day, and 3 had a final dose of 250 
mg/day. Twenty-three patients had an initial apatinib dose of 
425 mg/day. No significant correlation was found between the 
initial apatinib dose and the onset of delayed administration 
or grade 3/4 AEs. The specifics of the initial dose, delayed 
administration, and dose modification of apatinib are shown 
in Supplementary Table S2.
Most AEs were grade 1–2 and were well tolerated (Table 2). 
The most common AEs included gastrointestinal reaction, 
myelosuppression, and hypertension. One patient was hospi-
talized for grade 3 symptomatic thrombocytopenia. Among 
the patients with an initial apatinib dose of 500 mg/day, the 
incidence of grade 3/4 AEs was 58.8%, which was higher than 
that in the patients with an initial dose of 425 mg/day (43.5%) 
(Supplementary Table S3).
The main drug-related specific AEs, the median time of 
first delayed administration, and the median time of first dose 
modification were analyzed from the initiation of combined 
treatment (Supplementary Table S4).
Efficacy
Thirty-three patients had disease progression, and 28 patients 
died. The median PFS was 5.2 months (95% CI, 3.4–7.0 
months, Figure 1A), and the median OS was 17.4 months 
(95% CI, 8.0–27.0 months, Figure 1B). Among the 35 patients 
with evaluable efficacy, 6 (17.1%) achieved a better response 
to PR, 23 (65.7%) achieved SD, and the ORR was 17.1% 
(6/35). Sixteen patients achieved PR or remained in SD for 
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Table 2 Summary of adverse events











Myelosuppression (hematology)  27 (67.5)   21 (52.5)   6 (15.0)
Leukopenia   22 (55.0)   20 (50.0)   2 (5.0)
Neutropenia   22 (55.0)   17 (42.5)   5 (12.5)
Thrombocytopenia   10 (25.0)   9 (22.5)   1 (2.5)
Decreased hemoglobin   9 (22.5)   9 (22.5)   0 (0)
Gastrointestinal reaction   28 (70.0)   19 (47.5)   9 (22.5)
Nausea   23 (57.5)   22 (55.0)   1 (2.5)
Diarrhea   19 (47.5)   13 (32.5)   6 (15.0)
Vomiting   12 (30.0)   10 (25.0)   2 (5.0)
Hypertension   25 (62.5)   15 (37.5)   10 (25.0)
Pain   24 (60.0)   19 (47.5)   5 (12.5)
Malaise   21 (52.5)   19 (47.5)   2 (5.0)
Anorexia   20 (50.0)   19 (47.5)   1 (2.5)
Elevated transaminase   19 (47.5)   19 (47.5)   0 (0)
Hand-foot skin reaction   19 (47.5)   16 (40.0)   3 (7.5)
Proteinuria   15 (37.5)   14 (35.0)   1 (2.5)
Elevated bilirubin   13 (32.5)   12 (30.0)   1 (2.5)
Mucositis   11 (27.5)   8 (20.0)   3 (7.5)
Hemorrhage   8 (20.0)   7 (17.5)   1 (2.5)
Sinus tachycardia   6 (15.0)   6 (15.0)   0 (0)
Elevated creatinine   3 (7.5)   3 (7.5)   0 (0)
> 24 weeks, and the CBR was 45.7% (16/35). The efficacy by 
number of treatment lines and HR expression is shown in 
Supplementary Table S5.
The median PFS was significantly longer for patients who 
showed clinical benefit (i.e., CR, PR, or SD for at least 24 weeks) 
(n = 16) than for those who did not (n = 19) [11.2 months 
(95% CI, 3.7–18.7 months) vs. 3.3 months (95% CI, 1.7–4.9 
months), respectively, P < 0.001, Figure 2]. Nevertheless, no 
significant OS difference was found between these patient 
groups (P = 0.271).
In the survival analysis, univariate analysis of the  correlation 
between the characteristics and treatment- related conditions 
and PFS/OS was performed (Table 3). The results showed 
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Figure 1 Kaplan-Meier curve of progression-free survival (PFS) 
and overall survival (OS) in patients with pretreated advanced 
breast cancer who received apatinib combined therapy. (A) Kaplan-
Meier curve of PFS, indicating a median PFS of 5.2 months (95% CI: 
3.4–7.0); (B) Kaplan-Meier curve of OS, indicating a median OS of 
17.4 months (95% CI: 8.0–27.0).
Clinical benefit (+)
Clinical benefit (–)




























Figure 2 Kaplan-Meier curve of PFS comparing patients who 
achieved a clinical benefit after apatinib combined therapy, with a 
median PFS of 11.2 months, and those who did not, with a median 
PFS of 3.3 months. A statistically significant difference was found 
between these patient groups (P < 0.001).
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Variables  
 
PFS     OS  
Median PFS 
(months, 95% CI)
  P Median OS 
(months, 95% CI)
  P
Grade 3/4 adverse event
 No   5.1 (1.7–8.4)   0.361  17.4 (4.7–30.2)   0.414
 Yes   5.4 (3.3–7.5)     14.7 (6.8–22.6)  
Delayed administration
 No   3.6 (1.4–5.8)   0.008  15.8 (2.4–29.2)   0.728
 Yes   7.0 (3.3–10.6)     18.2 (8.1–28.4)  
PFS, progression-free survival; OS, overall survival.
Table 3 Subgroup analysis comparing median PFS and OS among 
patients with different characteristics
Variables  
 
PFS     OS  
Median PFS 
(months, 95% CI)
  P Median OS 
(months, 95% CI)
  P
Age, years        
 < 55   4.4 (3.0–5.8)   0.159  24.7 (10.3–39.0)   0.408
 ≥ 55   6.2 (2.5–9.9)     15.6 (10.0–21.3)  
ECOG performance status
 0   6.1 (4.1–8.0)   0.022  22.0 (14.0–30.0)   0.242
 1   3.6 (1.6–5.7)     9.1 (1.9–16.2)  
Hormone receptor status
 Positive   4.4 (2.0–6.8)   0.194  18.2 (0.0–37.9)   0.744
 Negative   6.0 (4.1–7.8)     15.8 (11.9–19.7)  
Visceral metastasis
 No   4.8 (2.7–7.0)   0.579  22.0 (9.6–34.3)   0.884
 Yes   5.2 (3.2–7.2)     17.4 (10.0–24.8)  
Chest wall recurrence
 No   5.2 (3.2–7.2)   0.98   30.2 (16.7–43.7)   0.036
 Yes   4.8 (2.7–7.0)     14.7 (7.6–21.8)  
Number of metastatic sites
 < 3   5.2 (4.6–5.8)   0.684  22.1 (9.2–35.1)   0.816
 ≥ 3   4.4 (1.1–7.7)     17.4 (10.0–24.8)  
Lines of treatment
 < 3   6.1 (3.4–8.7)   0.875  17.4 (12.3–22.5)   0.734
 ≥ 3   5.2 (4.0–6.4)     24.7 (11.2–38.1)  
Initial dose of apatinib
 425 mg/day   3.7 (2.6–4.9)   0.100  14.7 (5.2–24.2)   0.542
 500 mg/day   7.0 (3.5–10.5)     22.0 (13.5–30.5)  
Hypertension        
 No   4.4 (2.5–6.3)   0.587  15.6 (1.8–29.5)   0.563
 Yes   5.4 (4.0–6.8)     18.2 (8.2–28.3)  
Hand-foot skin reaction
 No   5.1 (3.7–6.4)   0.951  14.7 (7.7–21.7)   0.516
 Yes   5.4 (3.2–7.5)     22.0 (15.3–28.7)  
Proteinuria        
 No   4.4 (2.6–6.1)   0.271  14.7 (10.4–18.9)   0.555
 Yes   8.1 (5.2–11.0)     22.1 (13.9–30.4)  
Table 3 Continued
significant prolongation of median PFS in patients with an 
ECOG PS score of 0 (P = 0.022) and delayed administration 
during treatment (P = 0.008) (Figure 3A and 3B).
Variables including age, hormone receptor, ECOG PS, apat-
inib initial dose, proteinuria, and delayed administration were 
included in multivariate Cox proportional hazard models pre-
dicting PFS. An ECOG PS score of 0 and delayed administra-
tion remained independent predictive factors of PFS (Figure 
3A, 3B, Table 4). In addition, chest wall recurrence was an 
independent predictor of OS (P = 0.025) (Supplementary 
Table S6).
Patient characteristics for ctDNA analysis and 
detection of mutation profiling in ctDNA
Twenty patients had their first blood drawn at baseline 
(Supplementary Table S7). A total of 52 blood samples 
were collected, and 57 variant alterations were detected. The 
most frequently altered genes at baseline were TP53 (35%), 
PIK3CA (25%), PTEN (15%), ERBB2 (10%), and FGFR1 
(10%). The distribution of the main genomic alterations is 
shown in Figure 4. Specific genomic alterations at baseline 
and serial monitoring of alterations in ctDNA are shown in 
Supplementary Table S8.
The associations between baseline gene 
variants and PFS/OS
In analysis of genomic alterations in ctDNA at baseline, the 
median PFS was significantly longer for patients without 
detectable gene variants in ctDNA [13.9 months (95% CI, 
0.0–31.8 months) vs. 3.6 months (95% CI, 1.6–5.7 months), 
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P = 0.018, Figure 5A]. The median value of the maximum var-
iant allele frequency (maxVAF) was used as the cutoff value 
(0.985%). Patients whose maxVAF was less than the median 
value achieved longer PFS than those with higher maxVAF 
[7.0 months (95% CI, 3.1–10.8 months) vs. 3.3 months (95% 
CI, 0.8–5.8 months), P = 0.037, Figure 5B]. No statistically sig-
nificant difference was found in the analysis of OS.
Dynamic changes in ctDNA gene alterations 
during follow-up
A total of 12 patients had blood drawn at baseline, and at 
least one blood sample was collected at the subsequent time 
points. Four patients were free from genomic alterations at 
baseline and during treatment, whereas 8 patients displayed 
genomic alterations in ctDNA. The entire follow-up of these 
patients and the patterns of changes in ctDNA are shown in 
Supplementary Figure S1.
Discussion
This is the first study exploring the efficacy and safety of apa-
tinib combined with oral vinorelbine for the treatment of 
mBC. In this study, nearly half the patients (19/40, 47.5%) had 
already received at least 2-line metastatic treatment.
The patients enrolled in our study were all HER2-negative. 
Notwithstanding the limits imposed by comparing different 
studies, our subgroup analysis of patients with TNBC showed 
better efficacy than that of the single-agent treatment in Hu’s 
study17. The median PFS and OS of HR-positive patients were 
also longer in our study than in a non-TNBC apatinib sin-
gle-agent study16, although a discrepancy in the molecular 
subtypes of these 2 studies makes the studies poorly compa-
rable. Most previous studies of vinorelbine combined with 
chemotherapy (mainly capecitabine) have focused on first-
line therapy for advanced BC. A recent pooled analysis for 
stage II–III clinical trials of oral or intravenous vinorelbine 
plus capecitabine45 has suggested that combined therapy for 
second-line treatment has an ORR of 41.0%, a median PFS of 
3.8 months, and a median OS of 11.3 months. All our patients 
received apatinib plus oral vinorelbine as a second-line treat-
ment or beyond, and our data showed that the median PFS 
and OS for second-line treatment were 4.8 months and 14.7 
months, respectively, with an ORR of 20.0%. Compared with 
the efficacy of previous vinorelbine combined chemotherapy, 
ECOG PS = 0 6.1 (4.1–8.0)
ECOG PS = 1 3.6 (1.6–5.7)






























































Figure 3 Kaplan-Meier curve of progression-free survival (PFS) 
with statistical significance in subgroups. (A) Kaplan-Meier curve of 
PFS comparing patients whose ECOG PS score was 0, with a median 
PFS of 6.1 months (95% CI: 4.1–8.0), and those whose ECOG PS score 
was 1, with a median PFS of 3.6 months (95% CI: 1.6–5.7). A statisti-
cally significant difference was found between these patient groups 
(P = 0.022); (B) Kaplan-Meier curve of PFS comparing patients who 
experienced administration delay, with a median PFS of 7.0 months 
(95% CI: 3.3–10.6), and those who did not, with a median PFS of 3.6 
months (95% CI: 1.4–5.8). A statistically significant difference was 
found between these patient groups (P = 0.008).
Table 4 Multivariate Cox proportional hazard models predicting 
PFS for patients receiving combined therapy
Variables HR (95% CI) P value
Age (< 55/≥ 55) 1.106 (0.513–2.383) 0.798
Hormone receptor (neg/pos) 0.716 (0.320–1.604) 0.417
ECOG PS (0/1) 0.249 (0.085–0.734) 0.012
Apatinib initial dose  
(425 mg/500 mg)
0.838 (0.306–2.297) 0.732
Proteinuria (no/yes) 1.349 (0.596–3.053) 0.472
Delayed administration (no/yes) 5.065 (1.909–13.435) 0.001
PFS, progression free survival; ECOG PS, Eastern Cooperative 
Oncology Group Performance Statues.
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the PFS and OS for our combination therapy as a second-line 
treatment were both longer, although the ORR did not 
improve. A recent Chinese randomized clinical trial compar-
ing vinorelbine and eribulin mesylate has reported a median 
PFS and median OS for vinorelbine of 2.8 months and 12.5 
months in patients with locally recurrent BC or mBC who 
had at least 2 prior regimens46, whereas our results in patients 
who had received at least 2 regimens showed longer PFS and 
OS (5.2 months and 27.0 months, respectively). Because PFS 
and OS are the main objectives in clinical practice, apatinib 
plus oral vinorelbine as a second-line treatment for mBC may 
offer better disease control. Simultaneously, our combined 
therapy may be considered in patients with at least 2 prior 
regimens.
Beyond its anticancer activity against angiogenesis, apati-
nib was found to reverse multidrug resistance by decreasing 
expression of P-glycoprotein (ABCB1) and BC resistance 
protein (ABCG2) in vitro. It also effectively enhanced the drug 
susceptibility of drug-resistant cell lines. Further studies have 
demonstrated that a certain concentration of apatinib signif-
icantly increases the toxicity of chemotherapy agents such as 
taxane and vinca alkaloids14,15. On the basis of the knowledge 
regarding the antitumor mechanism and the potential effi-
cacy of apatinib combined with chemotherapy gained from 
this study, we conclude that synergistic or additive effects may 
exist between apatinib and chemotherapy. The combination of 
apatinib and oral vinorelbine may be a promising treatment 
after failure of other therapies for advanced BC. Therefore, 
the development of therapies in subsequent research is highly 
important.
The major AEs in our study were gastrointestinal reac-
tion, myelosuppression, hypertension, pain, malaise, ano-
rexia, elevated transaminase, and hand-foot skin reaction 
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Figure 4 Distribution of the main genomic alterations in the entire population at baseline.
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AEs (hypertension, diarrhea, and neutropenia) were reversed 
after symptomatic treatment, delayed administration, or dose 
 modification, thus suggesting that collecting patient infor-
mation before treatment may be advisable. The incidence of 
grade 3–4 AEs was decreased by downregulation of the initial 
dosage of apatinib in late-enrolled patients, but no significant 
difference in efficacy between these dose groups was noted. 
Therefore, we recommend an initial dose of apatinib of 425 
mg/day in combination therapy.
Our study also showed that patients who gained clinical 
benefit after combination therapy achieved longer PFS, thus 
implying that an ideal short-term outcome predicts good dis-
ease control. Huang et al.47 have found that the response to 
apatinib is significantly associated with clinical outcomes in 
advanced gastric cancer, a finding consistent with our data.
Our study found that patients with an ECOG PS score of 0 
had longer PFS, thereby suggesting that patients in good con-
dition are more likely to benefit. Previous studies on the treat-
ment of solid tumors have shown that patients with ECOG 
PS scores of ≥ 2 often have poorer outcomes48,49. Therefore, 
our results confirm that patients with better health assessment 
scores would benefit more, thus indicating that patient health 
condition is essential in evaluating treatment choices50.
Our multivariate analysis additionally showed that the 
treatment schedule may affect PFS. For example, patients 
with at least one delayed administration had significantly 
longer PFS than those who strictly followed the schedule. 
The leading cause of delayed administration was the onset of 
AEs, and hence the duration of treatment was longer for these 
patients. The efficacy and AEs may simultaneously increase 
in patients with higher blood concentrations, whereas drug 
susceptibility differs because of different targets among indi-
viduals. Given the potential therapeutic value of apatinib 
combined with oral vinorelbine, the optimal administra-
tion pattern for improving compliance and efficacy should 
be further investigated. Although our study did not find a 
significant difference in PFS or OS between HR-positive and 
HR-negative patients, the efficacy results suggested a signifi-
cantly improved ORR in patients with TNBC compared with 
HR-positive individuals. Microvessel density is an important 
biomarker of tumor angiogenesis51,52, and high expression 
of VEGF/VEGFR is associated with greater vascular den-
sity53. Previous studies have found increased tumor VEGF 
levels in TNBC54. However, VEGFR, particularly VEGFR2, is 
simultaneously expressed with VEGF on the tumor endothe-
lium53. Therefore, tumor microvessel density might increase 
in TNBC with high expression of VEGF/VEGFR, thus lead-
ing to a greater benefit from antivascular therapy. However, 
larger samples of clinical studies are needed to validate this 
analysis.
In the current study, we also explored the roles of ctDNA 
variants during antiangiogenic combination therapy. PFS 
was relatively shorter in patients with more mutations/
variants or with higher frequencies of ctDNA alterations. 
Recently, Rossi et al.55 have longitudinally detected ctDNA 
in patients with mBC, in whom the number of mutations 
in ctDNA along with the maximum mutant allele fraction 
at baseline were both predictive of progression and death. 
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Figure 5 Kaplan-Meier curve of progression-free survival (PFS) in 
subgroups with ctDNA at baseline. (A) Kaplan-Meier curve of PFS 
comparing patients with detected gene variants and those with-
out gene variants in ctDNA at baseline. The median PFS was sig-
nificantly longer for patients who had no gene variants detected in 
ctDNA compared with patients who had detectable gene variants 
[13.9 months (95% CI, 0.0–31.8 months) vs. 3.6 months (95% CI, 1.6–
5.7 months), P = 0.018]. (B) Kaplan-Meier curve of PFS comparing 
patients with different values of maxVAF in ctDNA. Patients whose 
maxVAF was less than the median value (0.985%) achieved longer 
PFS than those with higher maxVAF [7.0 months (95% CI, 3.1–10.8 
months) vs. 3.3 months (95% CI, 0.8–5.8 months), P = 0.037].
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ctDNA are significantly associated with poorer outcomes. 
Regarding the factors predicting the efficacy of antiangi-
ogenic-based therapy, no efficient biomarkers have been 
identified to date. Most studies have focused on the plasma 
or tissue levels of specific protein expression and single 
nucleotide polymorphisms in the VEGF signaling pathway. 
Nevertheless, all these biomarkers lack validation in further 
clinical studies. For the exploration of gene mutations, a sin-
gle-arm, phase II study of  apatinib in refractory metastatic 
colorectal cancer has analyzed a panel of 1,021 cancer-re-
lated genes by ctDNA, but has not found any positive results 
associated with PFS or OS56. One possible explanation is that 
by blocking VEGF signal transduction, antiangiogenic ther-
apies act not only on tumor cells but also on the microenvi-
ronment57,58, thus making identification of a biomarker in 
ctDNA difficult. Our investigation revealed an association 
between gene alterations in ctDNA at baseline and outcomes 
during antiangiogenic-based therapy, thus demonstrating 
that clinical outcomes depend on somatic variants, in terms 
of both mutation burden and frequency. However, the asso-
ciation between tumor mutation burden and therapeutic 
effects is more frequently discussed in immune therapies. 
Our exploration of ctDNA was based on a single arm study 
with a small sample size. The nature of the study (e.g., the 
absence of a control arm) did not enable clarification of the 
predictive or prognostic role of ctDNA. Larger randomized 
controlled double-blind clinical trials should be conducted 
to identify possible biomarkers for effective prediction.
Despite the limited data for the patients with ctDNA 
examined and the impossibility of distinguishing the pre-
dictive or prognostic role, some results of the exploratory 
analysis deserve further discussion. One patient originally 
treated with letrozole had an ESR1 mutation at baseline 
before combined treatment, thus demonstrating that endo-
crine therapy resistance might occur59-61. Two additional 
patients with HER2-negative primary tumors had acquired 
ERBB2 amplification in ctDNA at baseline sampling before 
combined treatment, thus suggesting clonal evolution 
toward a more aggressive subtype62. This finding may indi-
cate that patients could benefit from anti-HER2 therapy. 
Another patient with triple- negative BC had EGFR amplifi-
cation in ctDNA at baseline, and the copy number was high-
est when the disease progressed. According to ctDNA detec-
tion, patients with EGFR amplification may be considered 
for targeted therapy with lapatinib and may benefit from 
this approach63. Overall, these findings suggest that ctDNA 
detection might provide effective information for treatment 
guidance64.
Serial monitoring could be performed in only 8 patients. 
Dynamic changes in mutations and copy number variants 
in ctDNA can provide useful data in terms of response to 
treatment, particularly the association between PIK3CA/
TP53 mutation and tumor burden. This finding supports the 
results of previous studies42,63. Some variants not originally 
detected appeared during treatment, thus reflecting treatment 
resistance and/or clonal evolution65. A patient was identified 
to bear PDGFRA and KIT amplification when the disease 
progressed. Alterations in these genes are involved in PDGF 
signaling pathway activation, which is associated with tumor 
angiogenesis66-68. A previous study has shown that PDGFR 
expression may reflect VEGF signaling pathway resistance, and 
consequently that inhibition of VEGFR-2 plus PDGFR induces 
tumor vessel regression69,70. In our study, no genetic variations 
were detected in 4 patients from baseline to progression until 
the last follow-up. A possible explanation is that alterations 
were not present within the detectable variants in our panel. 
Hence, we believe that whole-exome analysis of plasma ctDNA 
should be performed to explore heterogeneity and evolution-
ary cloning in BC to clarify the mechanism of drug resistance.
Conclusions
In conclusion, this prospective study shows that apatinib com-
bined with oral vinorelbine may enable good disease control 
in patients with HER2-negative mBC who previously received 
treatments that failed. Patients in better condition and those 
with delayed administration achieved longer PFS. The main 
AEs were similar to those of apatinib or vinorelbine alone, and 
were limited through use of appropriate care. Full oral admin-
istration was more acceptable, particularly in patients who had 
received intravenous therapy for a long time. To our knowl-
edge, this is the first study demonstrating a potential clinical 
role of liquid biopsy applied to antiangiogenic combination 
therapy. The results of ctDNA target sequencing indicated that 
the mutation burden and VAF of ctDNA may be informative 
in antiangiogenic-based therapies. Patients with gene variants 
or higher VAF displayed poorer outcomes. A dynamic change 
in ctDNA might thus mirror gene clonal shifts, disease pro-
gression or resistance. However, the results of our ctDNA 
research remain to be further explored, owing to the small 
sample size in this study. Additional prospective studies with 
large randomized controlled trials may be needed to assess 
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the long-term clinical benefits. Our results also implied that 
the resistance mechanism of angiogenic therapy, particularly 
in combination therapy, may be highly complicated. Further 
validation of our findings in a larger number of patients, with 
adequate control arms and comprehensive analysis of multi-
omics data, is needed.
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